Table 2.
Figures and assumptions used for the calculations.
| MI | MI + CHF | ||
| Proportion of practice population of 10,000 | .056 [9] | .006 [10,11] | |
| Proportion eligible for treatment | |||
| ACE-I | .75 | .75 | |
| BB | .75 | .75 | |
| Aspirin | .90 | N/a | |
| Statins | .80 | N/a | |
| Spironolactone | N/a | .75 | |
| Proportion eligible for incremental treatment – (proportion currently on treatment) |
|||
| ACE-I | .27 (.48) | .16 (.59) | |
| BB | .43 (.32) | .43 (.32) | |
| Aspirin | .19 (.71) | N/a | |
| Statins | .61 (.19) | N/a | |
| Spironolactone | N/a | .55 (.20) | |
| Baseline risk of death in the next year expressed as a proportion |
.09 [10] | .29 [10] | |
| RRR from trials. | |||
| ACE-I | .16 [15] | .15 [3] | |
| BB | .23 [16] | .21 [17] | |
| Aspirin | .12 [4] | N/a | |
| Statins | .21 [18] | N/a | |
| Spironolactone | N/a | .30 [19] | |
| Costs (from MIMS, 2001) | |||
| ACE-I (Ramipril 2.5 mg @ €7.51/28; Lisinopril 10 mg @9.70/28) | €100 per year | €100 per year | |
| BB (Atenolol 25 mg @ €4.40/28; Metoprolol 100 mg @€6.68/56) | €45 per year | €45 per year | |
| Spironolactone 100 mg @ €39.50/100 | €144 per year | ||
| Aspirin @ 94p/28 | €11 per year | ||
| Statins (Simvastatin 20 mg or Pravastatin 20 mg@ €29.69/28) | €386 per year | ||